Literature DB >> 12601525

Cytokine-facilitated priming of CD8+ T cell responses by DNA vaccination.

Marcin Kwissa1, Andrea Kröger, Hansjörg Hauser, Jörg Reimann, Reinhold Schirmbeck.   

Abstract

Immune responses elicited by plasmid DNA vaccination can be enhanced and modulated by codelivery of cytokine-encoding plasmids. We studied whether priming of cytotoxic T lymphocyte (CTL) responses against hepatitis B surface antigen (HBsAg) by DNA vaccines injected either intramusculary or intradermally with the gene gun is enhanced by codelivery of cytokine-encoding plasmids. From a panel of tested cytokine plasmids only mouse IFNbeta, IL-15, and GM-CSF encoding plasmids showed an effect. Intradermal gene gun vaccination with 1 micro g plasmid DNA encoding intracellular HBsAg (large LS) showed enhanced CTL priming when IFNbeta, IL15, or GM-CSF encoding plasmids were codelivered; this was not observed when a DNA vaccine encoding secreted HBsAg (small S) was injected. Intramuscular injection of low (5 micro g) doses of a DNA vaccine encoding large HBsAg did not prime CTL when delivered without cytokines, with IFNbeta or IL15-encoding plasmids. However, codelivery with GM-CSF encoding plasmid DNA primed potent, specific CTL immunity detected either in a cytotoxic assay or by determining the frequency of L(d)-restricted CD8(+) T cells specifically inducible to IFNgamma production. The codelivery of GM-CSF encoding plasmids with the DNA vaccine furthermore enhanced CTL priming to a subdominant, D(d)-restricted epitope of HBsAg. The adjuvant effect of cytokine-encoding plasmids on CTL priming by DNA vaccines is thus complex and depends on: (a) the type of cytokine (or combination of cytokines) codelivered, (b) the type (intracellular vs. secreted) and dose (1-50 micro g) of the DNA vaccine, (c) the method of DNA vaccine delivery ("naked" vs. particle-coated DNA), and (d) the (intramuscular vs. intradermal) route of delivery of the DNA vaccine.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12601525     DOI: 10.1007/s00109-002-0395-6

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  9 in total

Review 1.  Technologies for enhanced efficacy of DNA vaccines.

Authors:  Fadi Saade; Nikolai Petrovsky
Journal:  Expert Rev Vaccines       Date:  2012-02       Impact factor: 5.217

2.  Utilizing IL-12, IL-15 and IL-7 as Mucosal Vaccine Adjuvants.

Authors:  Liljana Stevceva; Marcin Moniuszko; Maria Grazia Ferrari
Journal:  Lett Drug Des Discov       Date:  2006       Impact factor: 1.150

3.  Real-time immune monitoring to guide plasmid DNA vaccination schedule targeting prostatic acid phosphatase in patients with castration-resistant prostate cancer.

Authors:  Douglas G McNeel; Jordan T Becker; Jens C Eickhoff; Laura E Johnson; Eric Bradley; Isabel Pohlkamp; Mary Jane Staab; Glenn Liu; George Wilding; Brian M Olson
Journal:  Clin Cancer Res       Date:  2014-05-21       Impact factor: 12.531

Review 4.  Functions of IL-15 in anti-viral immunity: multiplicity and variety.

Authors:  Katherine C Verbist; Kimberly D Klonowski
Journal:  Cytokine       Date:  2012-06-15       Impact factor: 3.861

5.  Bicistronic woodchuck hepatitis virus core and gamma interferon DNA vaccine can protect from hepatitis but does not elicit sterilizing antiviral immunity.

Authors:  Jinguo Wang; Shashi A Gujar; Lucyna Cova; Tomasz I Michalak
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

Review 6.  Innovative strategies for co-delivering antigens and CpG oligonucleotides.

Authors:  Yogita Krishnamachari; Aliasger K Salem
Journal:  Adv Drug Deliv Rev       Date:  2009-01-19       Impact factor: 15.470

7.  Improved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypes.

Authors:  Wibke Bayer; Ruth Lietz; Teona Ontikatze; Lena Johrden; Matthias Tenbusch; Ghulam Nabi; Simone Schimmer; Peter Groitl; Hans Wolf; Cassandra M Berry; Klaus Uberla; Ulf Dittmer; Oliver Wildner
Journal:  Retrovirology       Date:  2011-09-26       Impact factor: 4.602

8.  A BCR/ABL-hIL-2 DNA vaccine enhances the immune responses in BALB/c mice.

Authors:  Yanan Qin; Hongxia Tian; Guanming Wang; Chen Lin; Yangqiu Li
Journal:  Biomed Res Int       Date:  2013-06-06       Impact factor: 3.411

9.  Co-expression of IL-15 enhances anti-neuroblastoma effectivity of a tyrosine hydroxylase-directed DNA vaccination in mice.

Authors:  Madlen Marx; Maxi Zumpe; Sascha Troschke-Meurer; Diana Shah; Holger N Lode; Nikolai Siebert
Journal:  PLoS One       Date:  2018-11-19       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.